PT  - JOURNAL ARTICLE
AU  - Hay, James A.
AU  - Kissler, Stephen M.
AU  - Fauver, Joseph R.
AU  - Mack, Christina
AU  - Tai, Caroline G.
AU  - Samant, Radhika M.
AU  - Connolly, Sarah
AU  - Anderson, Deverick J.
AU  - Khullar, Gaurav
AU  - MacKay, Matthew
AU  - Patel, Miral
AU  - Kelly, Shannan
AU  - Manhertz, April
AU  - Eiter, Isaac
AU  - Salgado, Daisy
AU  - Baker, Tim
AU  - Howard, Ben
AU  - Dudley, Joel T.
AU  - Mason, Christopher E.
AU  - Nair, Manoj
AU  - Huang, Yaoxing
AU  - DiFiori, John
AU  - Ho, David D.
AU  - Grubaugh, Nathan D.
AU  - Grad, Yonatan H.
TI  - Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound: a retrospective cohort study
AID  - 10.1101/2022.01.13.22269257
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.01.13.22269257
4099  - http://medrxiv.org/content/early/2022/08/26/2022.01.13.22269257.short
4100  - http://medrxiv.org/content/early/2022/08/26/2022.01.13.22269257.full
AB  - Background The combined impact of immunity and SARS-CoV-2 variants on viral kinetics during infections has been unclear.Methods We characterized 2,875 infections from the National Basketball Association occupational health cohort identified between June 2020 and January 2022 using serial RT-qPCR testing. Logistic regression and semi-mechanistic viral RNA kinetics models were used to quantify the effect of variant, symptom status, age, infection history, vaccination and antibody titer to founder SARS-CoV-2 strain on the duration of potential infectiousness and overall viral kinetics. The frequency of viral rebounds was quantified under multiple cycle threshold (Ct) value-based definitions.Results Among individuals detected partway through their infection, 51.0% (95% credible interval [CrI]: 48.2-53.6%) remained potentially infectious (Ct<30) five days post detection, with small differences across variants and vaccination history. Only seven viral rebounds (0.7%; N=999) were observed, with rebound defined as 3+ days with Ct<30 following an initial clearance of 3+ days with Ct≥30. High antibody titers against the founder SARS-CoV-2 strain predicted lower peak viral loads and shorter durations of infection. Among Omicron BA.1 infections, boosted individuals had lower pre-booster antibody titers and longer clearance times than non-boosted individuals.Conclusions SARS-CoV-2 viral kinetics are partly determined by immunity and variant but dominated by individual-level variation. Since booster vaccination protects against infection, longer clearance times for BA.1-infected, boosted individuals may reflect a less effective immune response, more common in older individuals, that increases infection risk and reduces viral RNA clearance rate. The shifting landscape of viral kinetics underscores the need for continued monitoring to optimize isolation policies and to contextualize the health impacts of therapeutics and vaccines.Funding Supported in part by CDC contract 200-2016-91779, Emergent Ventures at the Mercatus Center, the Huffman Family Donor Advised Fund, the MorrisSinger Fund, the National Basketball Association, and the National Basketball Players Association.Competing Interest StatementCM, CGT, RMS and SC are employees of IQVIA, Real World Solutions. DJA is co-owner of Infection Control Education for Major Sports, LLC. GK, MM, MP, SK, AM, IE, DS, TB, BH, JTD and CEM are employees of TEMPUS labs. NDG and JRF have a consulting agreement for Tempus and receive financial support from Tempus to develop SARS-CoV-2 diagnostic tests. JD is an employee of the NBA. SMK and YHG have a consulting agreement with the NBA.Funding StatementSupported in part by CDC contract 200-2016-91779, Emergent Ventures at the Mercatus Center, the Huffman Family Donor Advised Fund, the MorrisSinger Fund, the National Basketball Association, and the National Basketball Players Association. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Residual de-identified viral transport media from anterior nares and oropharyngeal swabs collected from players, staff, vendors, and associated household members from a professional sports league were obtained from BioReference Laboratories. In accordance with the guidelines of the Yale Human Investigations Committee, this work with de-identified samples was approved for research not involving human subjects by the Yale Institutional Review Board (HIC protocol # 2000028599). This project was designated exempt by the Harvard Institutional Review Board (IRB20-1407).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode and data to regenerate these analyses, including individual cycle threshold value trajectories, are available at https://github.com/gradlab/SC2-kinetics-immune-history. https://github.com/gradlab/SC2-kinetics-immune-history